ASCO Update: BMS' Nivolumab, Merck KGaA's ERBITUX, Amgen's T-Vec, Pfizer's XALKORI, GSK's VOTRIE

New Stories

• Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered

  May 30, 2025 - - Australian Biotech

• Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics

  May 29, 2025 - - Latest News

• TGA approves new therapy for children with growth hormone deficiency

  May 29, 2025 - - Latest News

• AbbVie Australia appoints Dr Carly Levetan associate medical director

  May 29, 2025 - - Latest News

• For patients, it's about understanding their experience and accessing the touchpoints

  May 29, 2025 - - Latest News

• Priceline Pharmacy launches annual event with national menopause project

  May 28, 2025 - - Latest News

• Anne Ruston welcomes her reappointment to health and the addition of NDIS

  May 28, 2025 - - Latest News